REG - FTSE Russell Primary Health Props Assura plc Chesnara PLC - Primary Health Properties

AssuraAnnouncement

Wed 18:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250813:nRSM2344Va&default-theme=true

RNS Number : 2344V  FTSE Russell  13 August 2025

 

Primary Health Prop. (UK): Combination with Assura (UK)

Changes in FTSE UK Index Series

13 August 2025

 Following the shares and cash offer for Assura (UK, Constituent) by Primary
 Health Prop. (UK, constituent) being declared wholly unconditional, please see
 details of affected indexes and effective dates below:

 

 Primary Health Prop. (UK, BYRJ5J1) will remain in the FTSE 250 Index.

 Assura (UK, BVGBWW9) will be deleted from the FTSE 250 Index.

 Chesnara (UK, B00FPT8) will be added to the FTSE 250 Index and deleted from
 the FTSE SmallCap Index.

 All changes effective from 18 August 2025.

 Full details of index changes are available on the FTSE Russell website.

 

 

 

 For further information please contact FTSE Russell Client Services at
 info@ftserussell.com (mailto:info@ftserussell.com) or call:

Australia  +61 (0) 2 7228 5659
 Hong Kong  +852 2164 3333
 Japan      +81 3 6441 1430
 London     +44 (0) 20 7866 1810
 New York   +1877 503 6437

Alternatively, please visit our website at lseg.com/ftse-russell
 (http://www.lseg.com/ftse-russell)

 Terms of Use (http://www.ftserussell.com/legal/website-terms-use) | Copyright
 © 2025 FTSE Russell

Alternatively, please visit our website at lseg.com/ftse-russell
(http://www.lseg.com/ftse-russell)

Terms of Use (http://www.ftserussell.com/legal/website-terms-use) | Copyright
© 2025 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FTSDZGMRKFDGKZM